Skip to main content
Premium Trial:

Request an Annual Quote

ArcticZymes, Tataa Ink Sales, Distribution Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian enzymes firm ArcticZymes and Swedish gene expression profiling company Tataa Biocenter today announced a mutual sales and distribution deal covering Europe.

The terms of the agreement calls for Tataa to sell ArcticZymes' heat-labile enzymes for use in contamination control through its sales channels. Tataa will also integrate ArcticZymes' products into its range of courses.

Additionally, ArcticZymes will launch two reference gene panels and the ValidPrime kits series from Tataa. The kits offer for the first time a "rational and economical tool" for determining DNA contamination level, the companies said.

Financial and other terms of the deal were not disclosed.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.